Immune cell recovery: a crystal ball for sepsis survival?
NCT ID NCT07787780
First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time
Summary
This study looks back at medical records of adults with sepsis in the ICU to see if the way their immune cells (CD4+ and CD8+ T-cells) recover early on is linked to their chances of surviving 28 days. By grouping patients based on these recovery patterns, researchers hope to find clues that help identify who is at higher risk. No treatments are given; it is purely an observational study.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify high-risk sepsis patients earlier and tailor monitoring or treatment strategies.
- What could go wrong
- This is a retrospective observational study, so it cannot prove cause and effect. The findings may not apply to all sepsis patients or lead to direct changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
303 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult ICU patients with sepsis meeting Sepsis-3.0 criteria, who had at least two serial CD4⁺/CD8⁺ T-lymphocyte subset tests during ICU hospitalization. Retrospective observational cohort from single-center ICU database.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of sepsis according to Sepsis-3.0 criteria (infection plus SOFA score ≥2), admitted to intensive care unit * At least two sequential peripheral blood CD4⁺ and CD8⁺ T-cell absolute count measurements (T1 and T2) during ICU stay * Interval between T1 and T2 \> 3 days Exclusion Criteria: * Age \< 18 years old * Death within 24 hours after ICU admission * Lack of baseline T-lymphocyte subset testing within 72 hours of ICU admission * Receiving glucocorticoid or other immunosuppressive therapy at enrollment * Pregnancy or puerperium status * Critical clinical data missing for analysis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sepsis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sichuan Provincial People's Hospital, Intensive Care Unit
Chengdu, Sichuan, 610072, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Persistent inflammation, immunosuppression and catabolism syndrome (PICS): a new horizon for surgical critical care subtitle: cardiac dysfunction in older sepsis survivors subtitle: development of a designer Proline-Rich antimicrobial peptide chaperone protein inhibitor (DPC) for treating sepsis
- A randomized clinical trial of early empiric Anti-Mycobacterium tuberculosis therapy for sepsis in Sub-Saharan africa
- Tracing of real-time glu13Cose metabolism in human immune cells - intensive care unit
- Could a neck vein check replace a harder ultrasound for ICU fluid management?
- Sepsis alert system aims to speed up critical care response in hospitals
- Can tracking ambulance ventilators improve emergency breathing care?